Cargando…

N-Acetylcysteine Treatment May Compensate Motor Impairments through Dopaminergic Transmission Modulation in a Striatal 6-Hydroxydopamine Parkinson’s Disease Rat Model

Preventing degeneration and the loss of dopaminergic neurons (DAn) in the brain while mitigating motor symptoms remains a challenge in Parkinson’s Disease (PD) treatment development. In light of this, developing or repositioning potential disease-modifying approaches is imperative to achieve meaning...

Descripción completa

Detalles Bibliográficos
Autores principales:	Caridade-Silva, Rita, Araújo, Bruna, Martins-Macedo, Joana, Teixeira, Fábio G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10295771/ https://www.ncbi.nlm.nih.gov/pubmed/37371987 http://dx.doi.org/10.3390/antiox12061257

Ejemplares similares

Neuroinflammation and Parkinson’s Disease—From Neurodegeneration to Therapeutic Opportunities
por: Araújo, Bruna, et al.
Publicado: (2022)

Quantified Striatal Dopaminergic Denervation as Predictor for Motor Outcomes in Parkinson's Disease
por: Trinh, Ilene, et al.
Publicado: (2023)

Chondroitinase ABC reduces dopaminergic nigral cell death and striatal terminal loss in a 6-hydroxydopamine partial lesion mouse model of Parkinson’s disease
por: Fletcher, Edward J. R., et al.
Publicado: (2019)

Striatal Dopaminergic Loss and Dysphagia in Parkinson Disease
por: Kim, Ji Hwan, et al.
Publicado: (2023)

Heroin seeking becomes dependent on dorsal striatal dopaminergic mechanisms and can be decreased by N‐acetylcysteine
por: Hodebourg, Ritchy, et al.
Publicado: (2018)

Striatal But Not Extrastriatal Dopamine Receptors Are Critical to Dopaminergic Motor Stimulation
por: Wang, Yuhan, et al.
Publicado: (2017)

Prosaposin PS18 reduces dopaminergic neurodegeneration in a 6-hydroxydopamine rat model of Parkinson’s disease
por: Wu, Kuo-Jen, et al.
Publicado: (2023)

DA-9805, a Herbal Mixture, Restores Motor Manifestations in 6-Hydroxydopamine-induced Parkinson’s Disease Mouse Model by Regulating Striatal Dopamine and Acetylcholine Levels
por: Huh, Eugene, et al.
Publicado: (2022)

Lesioning of the Striatum Reverses Motor Asymmetry in the 6-Hydroxydopamine Rodent Model of Parkinsonism
por: Friehs, G. M., et al.
Publicado: (1991)

Modafinil Improves Catalepsy in a Rat 6-Hydroxydopamine Model of Parkinson’s Disease; Possible Involvement of Dopaminergic Neurotransmission
por: Vajdi-Hokmabad, Reza, et al.
Publicado: (2017)

NOD2 promotes dopaminergic degeneration regulated by NADPH oxidase 2 in 6-hydroxydopamine model of Parkinson’s disease
por: Cheng, Li, et al.
Publicado: (2018)

The Cortical and Striatal Gene Expression Profile of 100 Hz Electroacupuncture Treatment in 6-Hydroxydopamine-Induced Parkinson's Disease Model
por: Huo, Li-Rong, et al.
Publicado: (2012)

Striatal Dopaminergic Functioning in Patients with Sporadic and Hereditary Spastic Paraplegias with Parkinsonism
por: Kim, Ji Seon, et al.
Publicado: (2013)

Distinct Role of Striatal Functional Connectivity and Dopaminergic Loss in Parkinson’s Symptoms
por: Dukart, Juergen, et al.
Publicado: (2017)

Dopaminergic medication reduces striatal sensitivity to negative outcomes in Parkinson’s disease
por: McCoy, Brónagh, et al.
Publicado: (2019)

Molecular Imaging of Striatal Dopaminergic Neuronal Loss and the Neurovascular Unit in Parkinson Disease
por: Ivanidze, Jana, et al.
Publicado: (2020)

Preventive Vitamin A Supplementation Improves Striatal Function in 6-Hydroxydopamine Hemiparkinsonian Rats
por: Marie, Anaïs, et al.
Publicado: (2022)

Epothilone B Benefits Nigral Dopaminergic Neurons by Attenuating Microglia Activation in the 6-Hydroxydopamine Lesion Mouse Model of Parkinson’s Disease
por: Yu, Zhongyuan, et al.
Publicado: (2018)

Repressing PTBP1 fails to convert reactive astrocytes to dopaminergic neurons in a 6-hydroxydopamine mouse model of Parkinson’s disease
por: Chen, Weizhao, et al.
Publicado: (2022)

Dopaminergic Modulation of Striatal Inhibitory Transmission and Long-Term Plasticity
por: Nieto Mendoza, Elizabeth, et al.
Publicado: (2015)

GDNF Receptor Agonist Alleviates Motor Imbalance in Unilateral 6-Hydroxydopamine Model of Parkinson’s Disease
por: Renko, Juho-Matti, et al.
Publicado: (2020)

Striatal astrocytes engulf dopaminergic debris in Parkinson's disease: A study in an animal model
por: Morales, Ingrid, et al.
Publicado: (2017)

Differential effects of dopaminergic drugs on spontaneous motor activity in the common marmoset following pretreatment with a bilateral brain infusion of 6-hydroxydopamine
por: Ando, Kiyoshi, et al.
Publicado: (2017)

Alleviation of Methamphetamine Sensitization by Partially Lesioning Dopaminergic Terminals with 6-Hydroxydopamine in Nucleus Accumbens
por: Chen, Shu-Chun, et al.
Publicado: (2021)

Methamphetamine-Induced Dopamine-Independent Alterations in Striatal Gene Expression in the 6-Hydroxydopamine Hemiparkinsonian Rats
por: Cadet, Jean Lud, et al.
Publicado: (2010)

Application of the Physical Disector Principle for Quantification of Dopaminergic Neuronal Loss in a Rat 6-Hydroxydopamine Nigral Lesion Model of Parkinson's Disease
por: Fabricius, Katrine, et al.
Publicado: (2017)

Corrigendum to “Dopaminergic Modulation of Striatal Inhibitory Transmission and Long-Term Plasticity”
por: Nieto-Mendoza, Elizabeth, et al.
Publicado: (2017)

Achyranthes bidentata polypeptide protects dopaminergic neurons from apoptosis induced by rotenone and 6-hydroxydopamine
por: Peng, Su, et al.
Publicado: (2018)

Protective Effect of Amber Extract on Human Dopaminergic Cells against 6-Hydroxydopamine-Induced Neurotoxicity
por: Luo, Yuening, et al.
Publicado: (2022)

Dopaminergic modulation of motor network dynamics in Parkinson’s disease
por: Michely, Jochen, et al.
Publicado: (2015)

A Guide to the Generation of a 6-Hydroxydopamine Mouse Model of Parkinson’s Disease for the Study of Non-Motor Symptoms
por: Masini, Débora, et al.
Publicado: (2021)

Optogenetic Globus Pallidus Stimulation Improves Motor Deficits in 6-Hydroxydopamine-Lesioned Mouse Model of Parkinson’s Disease
por: Di Bisceglie Caballero, Sonia, et al.
Publicado: (2023)

Destruction of Dopaminergic Neurons in the Midbrain by 6-Hydroxydopamine Decreases Hippocampal Cell Proliferation in Rats: Reversal by Fluoxetine
por: Suzuki, Katsuaki, et al.
Publicado: (2010)

Erythropoietin improves neurobehavior by reducing dopaminergic neuron loss in a 6-hydroxydopamine-induced rat model
por: QI, CHEN, et al.
Publicado: (2014)

Abrogation of the Circadian Nuclear Receptor REV-ERBα Exacerbates 6-Hydroxydopamine-Induced Dopaminergic Neurodegeneration
por: Kim, Jeongah, et al.
Publicado: (2018)

The neurogenetics of exploration and exploitation: Prefrontal and striatal dopaminergic components
por: Frank, Michael J., et al.
Publicado: (2009)

Local striatal volume and motor reserve in drug-naïve Parkinson’s disease
por: Jeong, Seong Ho, et al.
Publicado: (2022)

Farnesol in combination with N-acetylcysteine against Staphylococcus epidermidis planktonic and biofilm cells
por: Gomes, Fernanda, et al.
Publicado: (2012)

Modulation of striatal glutamatergic, dopaminergic and cholinergic neurotransmission pathways concomitant with motor disturbance in rats with kaolin-induced hydrocephalus
por: Chen, Li-Jin, et al.
Publicado: (2022)

Electroacupuncture Produces the Sustained Motor Improvement in 6-Hydroxydopamine-Lesioned Mice
por: Yu, Yan, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_sm1c2f6jdm2gqdo2ubk8fg74g5